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Background: Studies suggest 24-h blood pressure (BP) variability has prognostic value for cardiovascular disease.
Several factors associated with high 24-h BP variability are also common among individuals with chronic kidney
disease (CKD). We hypothesized 24-h BP variability would be higher for individuals with versus without CKD.
Methods: We analyzed 1,022 Jackson Heart Study participants who underwent ambulatory blood pressure
monitoring (ABPM). Twenty-four hour BP variability was defined by two metrics: day-night standard deviation (SDdn)
and average real variability (ARV). CKD was defined as ACR ≥30 mg/g or eGFR <60 mL/min/1.73 m2.
Results: The mean SDdn of systolic BP (SBP) was 10.2 ± 0.2 and 9.1 ± 0.1 mmHg and the mean ARV of SBP was 9.2 ± 0.2
and 8.6 ± 0.1 mmHg for those with and without CKD, respectively (each p≤ 0.001). After adjustment for age and sex,
SDdn and ARV were 0.98 mmHg (95 % CI 0.59, 1.38) and 0.52 mmHg (95 % CI 0.18, 0.86), respectively, higher among
participants with versus without CKD. These differences were not statistically significant after further multivariable
adjustment including 24-h mean SBP. Older age, and higher total cholesterol and 24-h mean SBP were associated with
higher SDdn and ARV of SBP among participants with CKD. Mean SDdn and ARV of diastolic BP (DBP) were higher for
participants with versus without CKD but these associations were not present after multivariable adjustment.
Conclusion: Data from the current study suggest that CKD is associated with higher 24-h BP variability, but the
association is primarily explained by higher mean BP among those with CKD.
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Over 26 million American adults have chronic kidney
disease (CKD) [1], evidenced by estimated glomerular
filtration rate (eGFR) < 60 ml/min/1.73 m2 or albumin-
to-creatinine ratio (ACR) ≥ 30 mg/g. CKD is a substan-
tial public health challenge given its high prevalence and
association with adverse outcomes, including cardiovas-
cular disease (CVD) incidence and all-cause mortality
[2, 3]. Identifying factors that explain this increased
risk may provide guidance on the development of in-
terventions to reduce it.* Correspondence: pmuntner@uab.edu
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creativecommons.org/publicdomain/zero/1.0/Ambulatory blood pressure monitoring (ABPM) is
useful for the identification of phenotypes that cannot
be ascertained by blood pressure (BP) measurements in
the clinic setting. This includes the identification of
white coat hypertension, masked hypertension, circadian
BP patterns, and 24-h BP variability. Recent data have
suggested that 24-h BP variability has prognostic value
for CVD and mortality independent of mean BP [4–6].
For example, Hansen, et al. reported an association be-
tween higher 24-h BP variability and increased risk for
cardiovascular mortality and stroke in a pooled analysis
of 11 studies [4]. Autonomic dysfunction has been pro-
posed as a key factor underlying higher 24-h BP variabil-
ity [7]. Many individuals with CKD have autonomic
dysfunction and other factors associated with high 24-hrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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BP (SBP), and higher levels of inflammation are com-
mon among individuals with CKD [8–10]. Therefore, we
hypothesized that individuals with CKD would have
higher 24-h BP variability compared to their counter-
parts without CKD. To test this hypothesis, we
conducted an analysis of African-American adults
participating in the Jackson Heart Study.
Methods
Study participants
The Jackson Heart Study is a community-based observa-
tional study designed to identify risk factors for CVD in
African Americans. Details of the study design and re-
cruitment have been published previously [11–13]. In
brief, 5,301 African Americans ≥ 21 years of age were re-
cruited from the Atherosclerosis Risk in Communities
(ARIC) site in Jackson, Mississippi, and a representative
sample of urban and rural Jackson tri-county (Hinds,
Madison, and Rankin) residents, study volunteers,
randomly contacted individuals, and secondary family
members. Baseline data collection occurred between
September 2000 and March 2004. The study protocol
was approved by the Institutional Review Boards govern-
ing research in human subjects at the participating cen-
ters and all participants provided written consent.
Data collection
Data used for the current analysis were collected
through an in-home interview; a study examination
after an overnight fast; and, for a subset of partici-
pants (n = 1,148), 24-h ABPM. Information on age,
sex, education, income, cigarette smoking, and a history
of diabetes, stroke, or myocardial infarction were col-
lected during the study interview. During the clinic visit,
a standardized protocol was followed to obtain two BP
measurements, waist circumference was measured, and
blood and urine samples were collected. Information was
recorded on all medications, vitamins, mineral supple-
ments, and herbal or home remedies used within the
2 weeks prior to the participant’s interview [12].
Using the blood and urine samples collected during
the clinic visit, total and high-density lipoprotein (HDL)
cholesterol were assayed by the cholesterol oxidase
method supplied by Boehringer Mannheim Diagnostics
on a Roche COBAS Fara analyzer (Indianapolis, IN).
Serum c-reactive protein was measured with a high-
sensitivity immunoturbidimetric CRP-Latex assay (Kamiya
Biomedical Company, Washington) and levels > 3 mg/L
were defined as elevated. Urinary albumin was measured
with the Dade Behring BN II nephelometer (Newark,
Delaware). Serum and urine creatinine were mea-
sured using a multi-point enzymatic spectrophoto-
metric assay on a Vitros 950 Ortho-Clinical Diagnosticsanalyzer (Raritan, New Jersey). Creatinine values were
biochemically calibrated to Cleveland Clinic-equivalent
Minnesota Beckman CX3 assay for analysis purposes
[14]. eGFR was calculated via the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equa-
tion [1], and CKD was defined as ACR ≥ 30 mg/g or
eGFR < 60 mL/min/1.73 m2.
During the clinic visit, BP was measured after a 5-min
rest with a Hawksley random zero sphygmomanometer
equipped with one of four cuff sizes selected following
measurement of each participant’s arm circumference
(Hawksley and Sons Ltd). The average of the 2 measures
taken 1 min apart was used to define clinic BP. Upon
completion of the study visit, participants were asked to
complete an ABPM over the next 24 h. ABPM measure-
ments were obtained with a portable, noninvasive oscil-
lometric device (Spacelabs 90207; Medifacts International
Ltd, Rockville, MD) with a cuff fitted to the participant’s
non-dominant arm. Trained technicians instructed partici-
pants in the proper use of the ABPM device. With the par-
ticipant in the seated position, 3–5 simultaneous ABPM
and office sphygmomanometer BP readings were taken to
calibrate the ABPM device. The device was programmed
to measure BP every 20 min for 24 h, and participants
were instructed to proceed with their normal daily activ-
ities but keep their arm still and extended at their side
during each BP reading. Participants returned to the clinic
after 24 h for the removal of the device. The monitor was
connected to a computer and the BP readings were down-
loaded with commercially available software (Medicom,
version 3.41; Medifacts Ltd). Quality control was assured
by technician recertification, procedural checklists, and
data review [12, 15–17].
Assessment of 24-h BP variability
All BP readings were reviewed to eliminate out-of-range
readings and errors due to motion artifacts or equip-
ment problems, relying on predetermined acceptable
ranges of SBP and diastolic BP (DBP) [17]. Twenty-four
hour BP variability was defined by two metrics: day-
night standard deviation (SDdn) and average real vari-
ability (ARV). SDdn was calculated as a weighted average
of the daytime and nighttime standard deviation of SBP
and DBP, separately, during the ABPM period. The ARV
was calculated for SBP and DBP, separately, as the mean
of the absolute difference of consecutive BP measure-
ments during the ABPM period.
Statistical analysis
The current analysis was restricted to participants with
valid ABPM data based on the International Database of
Ambulatory Blood Pressure in relation to Cardiovascular
Outcome (IDACO) criteria, which requires 10 daytime
(defined as 10a-8p) and 5 nighttime (defined as 12p-6a)
Table 1 Characteristics of Jackson Heart Study participants with
and without chronic kidney disease
No CKD CKD p-value
(n = 849) (n = 173)
Age, years 58.9 (0.4) 60.8 (0.9) 0.041
Female gender, % 68.3 65.1 0.452
Less than high school education, % 18.1 26.7 0.022
Low income, % 10.8 15.6 0.142
Diabetes, % 21.2 40.6 <0.001
History of stroke, % 2.9 8.8 0.002
History of myocardial infarction, % 4.1 7.5 0.074
Current smoking, % 5.3 7.4 0.329
Waist circumference, cm 99.1 (0.5) 104.5 (1.3) <0.001
Total cholesterol, mg/dL 200.7 (1.4) 205.0 (3.5) 0.242
HDL-cholesterol, mg/dL 54.1 (0.5) 51.5 (1.0) 0.043
C-reactive protein > 3 mg/L, % 46.7 52.1 0.213
Mean clinic SBP, mmHg 126.0 (0.6) 132.9 (1.6) <0.001
Mean clinic DBP, mmHg 77.3 (0.4) 77.1 (0.9) 0.781
Mean 24-h SBP, mmHg 125.0 (0.4) 132.7 (1.4) <0.001
Mean 24-h DBP, mmHg 73.8 (0.3) 76.2 (0.9) 0.004
eGFR, mL/min/1.73 m2 94.4 (0.6) 77.7 (2.4) <0.001
Albumin-to-creatinine ratio,
mg/g
5.5 (3.7, 9.4) 55.3 (22.9, 125.5) <0.001
Antihypertensive medication
use, %
Aldosterone antagonist 1.6 4.9 0.073
Alpha blocker 11.6 16.9 0.152
ACE inhibitor 35.8 47.0 0.035
Angiotensin II receptor blocker 12.2 13.3 0.753
Beta blocker 24.1 18.6 0.234
Calcium channel blocker 32.6 47.2 0.008
Diuretic 65.6 65.4 0.971
Renin inhibitor NA NA —
Vasodilator 0.8 1.0 0.839
CKD chronic kidney disease, defined as an estimated glomerular filtration
rate < 60 mL/min/1.73 m2 or an albumin-to-creatinine ratio ≥ 30 mg/g;
HDL high-density lipoprotein, SBP systolic blood pressure, DBP diastolic
blood pressure, eGFR estimated glomerular filtration rate, ACE angiotensin
converting enzyme
Numbers in table are presented as mean (standard error) or percent except
albumin-to-creatinine ratio, which is presented as median (interquartile range)
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missing clinic SBP (n = 5), with end-stage renal disease
at baseline (n = 9), and without a serum creatinine meas-
urement at baseline (n = 10) were excluded. We used
multiple imputation (n = 10 data sets) and chained equa-
tions to impute ACR and other variables with missing
data. Additional file 1: Table S1 summarizes the percent-
age of participants with missing data prior to imput-
ation. We included 1,022 Jackson Heart Study
participants in the current analysis.
Participant characteristics and SDdn and ARV of SBP
and DBP were calculated for those with and without
CKD, separately. The statistical significance of differ-
ences across groups were calculated using t-tests and
chi-square tests, as appropriate. Next, using linear re-
gression, we calculated the adjusted differences in SDdn
and ARV of SBP and DBP for participants with, versus
without, CKD. Three levels of adjustment were per-
formed, using variables selected a priori. Initial models
included adjustment for age and sex. A second model
included age, sex, education, income, smoking status,
waist circumference, diabetes, history of stroke, history
of myocardial infarction, total cholesterol, HDL-
cholesterol, c-reactive protein, statin use, and antihyper-
tensive medication use. The full multivariable adjusted
model included the variables in the second model and
mean 24-h SBP in analyses of SDdn and ARV of SBP,
and mean 24-h DBP in analyses of SDdn and ARV of
DBP. Analyses were repeated comparing SDdn and ARV
of SBP and DBP between participants with eGFR less
than versus greater than or equal to 60 ml/min/1.73 m2
and ACR greater than or equal to versus less than
30 mg/g. Finally, for individuals with CKD, we calculated
differences in SDdn and ARV of SBP and DBP associated
with each study covariate included in full multivariable
adjusted models. All analyses were conducted using
Stata Version 13 (Stata Corp. College Station, TX).
Results
Participant characteristics
On average, compared to their counterparts without
CKD, participants with CKD were older, had a larger
waist circumference, a higher mean clinic and 24-h SBP
and DBP, and were more likely to be taking an
angiotensin-converting enzyme inhibitor or calcium
channel blocker (Table 1). Also, participants with CKD
had lower HDL-cholesterol compared to those without
CKD. Those with CKD were more likely to have less
than a high school education, diabetes, and a history of
stroke.
CKD and SDdn and ARV of SBP
SDdn of SBP was higher among participants with versus
without CKD (Table 2, top panel). After age and sex-adjustment and further adjustment for education, in-
come, smoking status, waist circumference, diabetes, his-
tory of stroke, history of myocardial infarction, total
cholesterol, HDL-cholesterol, c-reactive protein, statin
use, and antihypertensive medication use, SDdn of SBP
was higher for participants with versus without CKD.
The difference in SDdn of SBP for those with, versus
without, CKD was attenuated and not statistically sig-
nificant after further adjustment for mean 24-h SBP.
Table 2 Association of chronic kidney disease status,
albumin-to-creatinine ratio, and estimated glomerular filtration
rate with measures of systolic blood pressure variability
Chronic kidney disease status
Blood pressure variability
measure
No CKD CKD p-value
(n = 849) (n = 173)
Day-night standard deviation,
mmHg
Mean ± standard error 9.1 ± 0.1 10.2 ± 0.2 <0.001
Age, sex adjusted 0 (ref) 0.98 (0.59, 1.38) <0.001
Multivariable adjusted 1a 0 (ref) 0.64 (0.19, 1.09) 0.005
Multivariable adjusted 2b 0 (ref) 0.31 (−0.12, 0.74) 0.162
Average real variability, mmHg
Mean ± standard error 8.6 ± 0.1 9.2 ± 0.2 0.001
Age, sex adjusted 0 (ref) 0.52 (0.18, 0.86) 0.003
Multivariable adjusted 1a 0 (ref) 0.32 (−0.09, 0.72) 0.125




ACR < 30 ACR ≥ 30 p-value
(n = 885) (n = 137)
Day-night standard deviation,
mmHg
Mean ± standard error 9.2 ± 0.1 10.2 ± 0.3 <0.001
Age, sex adjusted 0 (ref) 1.09 (0.65, 1.53) <0.001
Multivariable adjusted 1a 0 (ref) 0.85 (0.33, 1.37) 0.001
Multivariable adjusted 2b 0 (ref) 0.35 (−0.16, 0.85) 0.179
Average real variability, mmHg
Mean ± standard error 8.7 ± 0.1 9.2 ± 0.2 0.01
Age, sex adjusted 0 (ref) 0.57 (0.18, 0.95) 0.004
Multivariable adjusted 1a 0 (ref) 0.41 (−0.06, 0.89) 0.085
Multivariable adjusted 2b 0 (ref) 0.05 (−0.41, 0.50) 0.844
Estimated glomerular filtration rate, mL/min/1.73 m2
Blood pressure variability
measure
eGFR≥ 60 eGFR < 60 p-value
(n = 960) (n = 62)
Day-night standard deviation,
mmHg
Mean ± standard error 9.3 ± 0.1 10.4 ± 0.4 <0.001
Age, sex adjusted 0 (ref) 0.58 (−0.04, 1.20) 0.066
Multivariable adjusted 1a 0 (ref) 0.24 (−0.39, 0.86) 0.455
Multivariable adjusted 2b 0 (ref) 0.17 (−0.42, 0.77) 0.565
Average real variability, mmHg
Mean ± standard error 8.7 ± 0.1 9.5 ± 0.2 0.004
Age, sex adjusted 0 (ref) 0.27 (−0.24, 0.78) 0.296
Multivariable adjusted 1a 0 (ref) −0.01 (−0.54, 0.52) 0.981
Multivariable adjusted 2b 0 (ref) −0.05 (−0.56, 0.46) 0.842
CKD chronic kidney disease, ACR albumin-to-creatinine ratio, eGFR estimated
glomerular filtration rate
aAdjusted for age, sex, education, income, smoking status, waist circumference,
diabetes, history of stroke, history of myocardial infarction, total cholesterol,
high-density lipoprotein cholesterol, c-reactive protein, statin use, and
antihypertensive medication use
bAdjusted for above model 1 plus mean 24-h systolic blood pressure
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CKD after age and sex adjustment, but this difference
was attenuated and no longer statistically significant
after further multivariable adjustment.
SDdn and ARV of SBP were higher among partici-
pants with ACR ≥ 30 mg/g versus their counterparts
with ACR < 30 mg/g (Table 2, middle panel). These
associations were attenuated and no longer statisti-
cally significant after multivariable adjustment includ-
ing mean 24-h SBP. SDdn and ARV of SBP were higher for
participants with eGFR < 60 mL/min/1.73 m2 compared to
their counterparts with eGFR ≥ 60 mL/min/1.73 m2
(Table 2, bottom panel). These differences were at-
tenuated and no longer statistically significant after
adjustment for age and sex or further multivariable
adjustment.
Among participants with CKD, older age, total choles-
terol, and higher 24-h SBP were associated with higher
SDdn and ARV of SBP (Additional file 2: Table S2).
Female gender and alpha blocker use were associated
with higher SDdn of SBP but not ARV of SBP. Higher
HDL-cholesterol was associated with lower ARV of SBP
among those with CKD.
CKD and SDdn and ARV of DBP
SDdn and ARV of DBP were higher for participants with
versus without CKD (Table 3, top panel). SDdn of DBP
was higher for participants with versus without CKD
after age, sex-adjustment and after further adjustment
for education, income, smoking status, waist circumfer-
ence, diabetes, history of stroke, history of myocardial
infarction, total and HDL-cholesterol, c-reactive protein,
statin use, and antihypertensive medication use. How-
ever, this association was attenuated and not statistically
significant after adjustment for mean 24-h DBP. The age
and sex-adjusted mean difference in ARV of DBP was
higher for individuals with CKD compared to those
without CKD, but this association was no longer statisti-
cally significant after further multivariable adjustment.
Compared to those with ACR < 30 mg/g, participants
with ACR ≥ 30 mg/g had higher SDdn of DBP and ARV
of DBP (Table 3, middle panel). This association was no
longer statistically significant after multivariable adjust-
ment including mean 24-h DBP. Differences in SDdn of
DBP and ARV of DBP between participants with
eGFR < and ≥ 60 mL/min/1.73 m2 were not statisti-
cally significant before or after multivariable adjust-
ment (Table 3, bottom panel).
Among participants with CKD, older age, larger waist
circumference and higher mean 24-h DBP were associ-
ated with higher SDdn and ARV of DBP (Additional
file 3: Table S3). Female gender was associated with
lower ARV of DBP but not SDdn of DBP among
those with CKD.
Table 3 Association of chronic kidney disease status,
albumin-to-creatinine ratio, and estimated glomerular filtration
rate with measures of diastolic blood pressure variability
Chronic kidney disease status
Blood pressure variability
measure
No CKD CKD p-value
(n = 849) (n = 173)
Day-night standard deviation,
mmHg
Mean ± standard error 8.0 ± 0.1 8.5 ± 0.2 0.004
Age, sex adjusted 0 (ref) 0.54 (0.17, 0.90) 0.004
Multivariable adjusted 1a 0 (ref) 0.43 (0.00, 0.85) 0.049
Multivariable adjusted 2b 0 (ref) 0.25 (−0.16, 0.66) 0.231
Average real variability, mmHg
Mean ± standard error 7.5 ± 0.1 7.9 ± 0.2 0.043
Age, sex adjusted 0 (ref) 0.37 (0.01, 0.72) 0.041
Multivariable adjusted 1a 0 (ref) 0.32 (−0.09, 0.72) 0.128
Multivariable adjusted 2b 0 (ref) 0.19 (−0.21, 0.59) 0.351
Albumin-to-creatinine ratio, mg/g
Blood pressure variability measure ACR < 30 ACR ≥ 30 p-value
(n = 885) (n = 137)
Day-night standard deviation,
mmHg
Mean ± standard error 8.0 ± 0.1 8.6 ± 0.2 0.002
Age, sex adjusted 0 (ref) 0.64 (0.23, 1.06) 0.002
Multivariable adjusted 1a 0 (ref) 0.63 (0.13, 1.13) 0.013
Multivariable adjusted 2b 0 (ref) 0.39 (−0.10, 0.87) 0.122
Average real variability, mmHg
Mean ± standard error 7.5 ± 0.1 8.1 ± 0.2 0.011
Age, sex adjusted 0 (ref) 0.53 (0.13, 0.93) 0.010
Multivariable adjusted 1a 0 (ref) 0.57 (0.09, 1.05) 0.021
Multivariable adjusted 2b 0 (ref) 0.39 (−0.09, 0.87) 0.108
Estimated glomerular filtration rate, mL/min/1.73 m2
Blood pressure variability measure eGFR ≥ 60 eGFR < 60 p-value
(n = 960) (n = 62)
Day-night standard deviation,
mmHg
Mean ± standard error 8.1 ± 0.1 8.2 ± 0.3 0.572
Age, sex adjusted 0 (ref) 0.17 (−0.39, 0.72) 0.551
Multivariable adjusted 1a 0 (ref) 0.07 (−0.50, 0.64) 0.805
Multivariable adjusted 2b 0 (ref) 0.01 (−0.55, 0.56) 0.977
Average real variability, mmHg
Mean ± standard error 7.6 ± 0.1 7.5 ± 0.2 0.655
Age, sex adjusted 0 (ref) −0.13 (−0.66, 0.41) 0.641
Multivariable adjusted 1a 0 (ref) −0.19 (−0.75, 0.36) 0.487
Multivariable adjusted 2b 0 (ref) −0.24 (−0.78, 0.30) 0.384
CKD chronic kidney disease, ACR albumin-to-creatinine ratio, eGFR estimated
glomerular filtration rate
aAdjusted for age, sex, education, income, smoking status, waist circumference,
diabetes, history of stroke, history of myocardial infarction, total cholesterol,
high-density lipoprotein cholesterol, c-reactive protein, statin use, and
antihypertensive medication use
bAdjusted for above model 1 plus mean 24-h diastolic blood pressure
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This population-based study of African American adults
suggests an association between CKD and higher SDdn
of BP and ARV of DBP. However, these associations
were explained by the higher mean 24-h BP among par-
ticipants with CKD. Older age, larger waist circumfer-
ence, and higher mean 24-h SBP were associated with
higher 24-h SBP variability. Female gender, larger waist
circumference, and higher mean 24-h DBP were associ-
ated with higher 24-h DBP variability.
Twenty-four hour BP variability has been associated
with adverse outcomes and may represent a novel CVD
risk factor. In a pooled analysis of 11 studies, Hansen,
et al. reported that ARV of BP was associated with total
and cardiovascular mortality (multivariable adjusted haz-
ard ratio [HR] for ARV of SBP: 1.11 (95 % confidence
interval [CI]: 1.04–1.18) and 1.17 (95 % CI: 1.07–1.28),
respectively; multivariable adjusted HR for ARV of DBP:
1.13 (95 % CI: 1.07–1.19) and 1.21 (95 % CI: 1.12–1.31),
respectively) [4]. Additionally, Eguchi, et al. reported
SD of nighttime SBP to be an independent risk factor
for the composite outcome of stroke, myocardial in-
farction, or sudden cardiac death (HR: 2.21; 95 % CI
1.08–4.53) [18].
Long-term BP variability (i.e. “visit-to-visit” variability)
has been associated with adverse outcomes among indi-
viduals with CKD in several studies [19–22]. For ex-
ample, in an analysis of 374 elderly patients with CKD,
DiIorio, et al. reported that each 1 % increase in visit-to-
visit BP variability was associated with a higher risk for
all-cause mortality (HR: 1.05 (95 % CI: 1.02–1.09) [19].
In an analysis of the African American Study of Kidney
Disease (AASK) trial, McMullan, et al. found an associ-
ation between visit-to-visit BP variability with all-cause
mortality and cardiovascular mortality (HR comparing
highest with lowest tertile of visit-to-visit BP variability:
2.82 (95 % CI: 1.14–6.95) and 4.91 (95 % CI: 1.12–
21.50), respectively) [20]. Although not extensively stud-
ied, 24-h BP variability has been associated with target
organ damage among individuals with CKD in at least
one study. Ryu, et al. reported that ARV of SBP was as-
sociated with left ventricular hypertrophy (odds ratio:
1.05 (95 % CI: 1.02–1.09)), but not kidney injury (defined
as eGFR <30 mL/min/1.73 m2 and proteinuria) in a large
sample of hypertensive CKD patients in Korea [23].
In the current analysis, CKD was associated with
higher 24-h BP variability, but this association was no
longer present after adjustment for mean 24-h BP. The
direction of the association between mean BP and BP
variability is unclear. For example, higher mean BP and
its associated sequelae (e.g., arterial stiffness) could lead
to higher BP variability. Alternatively, higher BP variabil-
ity could cause vascular injury, making BP harder to
control. Given the cross-sectional nature of our analysis,
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could prove helpful for characterizing this association.
Autonomic imbalance is a characteristic of BP variability
which has also been associated with CKD progression
[24] and may suggest a potential physiologic mechanism
for the association between 24-h variability and CKD.
Sympathetic nerve terminals innervate the kidneys dir-
ectly, potentially affecting tubular function by enhancing
solute and fluid resorption and modifying renal micro-
vascular function by enhancing the effects of angiotensin
[24–26]. Additionally, several CVD risk factors which
adversely affect the glomerulus (e.g. endothelial dysfunc-
tion, dyslipidemia, insulin resistance, and oxidative
stress) are also associated with high sympathetic and low
parasympathetic tone, suggesting a potential mechanism
involving the nervous system’s role in regulating
hemodynamics, vascular tone, metabolism, and inflam-
mation [24].
Strengths and limitations
Our study maintains several strengths, including the
large sample size of African American adults with avail-
able ABPM data and the availability of comprehensive
data which allowed us to adjust for potential con-
founders. However, the current findings should be con-
sidered in the context of certain limitations. The current
analysis employed a cross-sectional study design. Also,
eGFR and albuminuria were only assessed at a single
time point and therefore, misclassification of CKD status
may be present. We were not able to assess the effect of
plasma metanephrines, a marker of adrenergic activa-
tion, on 24-h BP variability. Finally, the applicability
of our results to race/ethnic groups beyond African
Americans needs to be assessed in other studies.
Conclusions
In conclusion, data from the current study suggest that
CKD may be associated with higher SDdn of SBP and
DBP and ARV of DBP over 24-h. However, these associ-
ations were no longer present after adjustment for 24-h
mean BP. Further studies with repeated measurements
of 24-h BP variability and mean BP are needed to deter-
mine the direction of the association. Such data may be
useful in identifying new therapeutic targets in an effort
to improve health outcomes for individuals with CKD.Additional files
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